- Asian equities dribble as welcome numbers at home fail to convince bulls.
- Vaccine hopes bolster, US fiscal stimulus likely out sooner.
- Aussie Q4 CPI improved, Chinese Industrial Production came in better-than-expected in December.
- Virus woes, doubts over the US relief package offer noisy background while markets await Federal Reserve.
Asian shares wobble during early Wednesday as traders await this year’s first US Fed announcement amid the coronavirus (COVID-19) woes. While portraying the mood, MSCI’s index of Asia-Pacific shares, ex-Japan, drops for the second day in a row, currently down 0.12% intraday, whereas Japan’s Nikkei 225 gains 0.26% on a day by press time.
It should, however, be noted that shares in Australia and China ignored upbeat data, concerning Consumer Price Index (CPI) and Industrial Profits respectively, to mark mild losses. Also weighing on the ASX 200 and stocks from Beijing are recently grave relations between the US and China over the South China Sea.
Elsewhere, shares from New Zealand and Hong Kong manage to cheer the vaccine hopes, with mild gains, as global covid vaccine producers show confidence to tame the virus variant. Also on the positive side were US President Joe Biden’s comments suggesting more vaccines and faster immunization. Furthermore, comments from U.S. Senate Majority Leader Chuck Schumer also boosted the expectations of the much-awaited American aid package. The Congress member recently said, “Democrats will move forward on President Joe Biden’s coronavirus relief plan without Republican support if necessary,” per Reuters.
It should be noted that the increase in COVID-19 infections in South Korea and Indonesia dragged KOSPI and IDX Composite down by 0.15% and 0.50% respectively while India’s BSE Sensex drops over 0.50% amid problems between farmers and the government.
On a broader scale, S&P 500 Futures mark mild losses after refreshing the record top the previous day. Further, the US 10-year Treasury yields stand pat near 1.04% as traders await the Fed.
Looking forward, updates on the US stimulus and covid can entertain markets but the Fed will be the key. Given the virus woes likely to push the Federal Reserve towards a dovish halt, any surprises won’t be taken lightly.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.